NEW YORK, July 10 – Molecular Devices has signed a definitive agreement to acquire Cytion, a Swiss developer of drug screening technology, for $7.5 million in cash and 400,000 shares of Molecular Devices stock, Molecular Devices said Tuesday.

Cytion, based in Epalinges, Switzerland, has developed a technique using automated patch clamping for analyzing ion channels, a class of proteins important as drug targets.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Robert Redfield is floated as the next director of the US Centers for Disease Control and Prevention, the Washington Post reports.

The New York Times writes that the National Institutes of Health's All of Us Research Program is "ambitious" and that some are concerned it might be overly so.

Representative Lamar Smith's criticism of the National Science Foundation has "changed the nature of the conversation," according to ScienceInsider.

In PLOS this week: non-coding RNA function in yeast, transcriptomic profiles of malaria parasites, and more.